Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 3
2017 3
2018 2
2019 5
2020 5
2021 6
2022 3
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Biomarkers of efficacy and safety of the academic BCMA-CART ARI0002h for the treatment of refractory multiple myeloma.
Oliver-Caldés A, Español-Rego M, Zabaleta A, Gonzalez-Calle V, Navarro-Velázquez S, Inoges S, López-Díaz de Cerio A, Cabañas V, López-Muñoz N, Rodriguez-Otero P, Reguera-Ortega JL, Moreno DF, Martínez-Cibrian N, López-Corral L, Pérez-Amill L, Martin-Antonio B, Rosinol L, Cid J, Tovar N, Saez-Peñataro J, Lopez-Parra M, Olesti E, Guillen E, Varea S, Rodríguez-Lobato LG, Battram AM, Gonzalez-Perez MS, Sanchez-Salinas A, González-Navarro A, Ortiz-Maldonado V, Delgado J, Prosper F, Juan M, Martinez-Lopez J, Moraleda JM, Mateos MV, Urbano-Ispizua A, Paiva B, Pascal M, Fernández de Larrea C. Oliver-Caldés A, et al. Among authors: olesti e. Clin Cancer Res. 2024 Mar 11. doi: 10.1158/1078-0432.CCR-23-3759. Online ahead of print. Clin Cancer Res. 2024. PMID: 38466644
Activation of endogenous glucocorticoids by HSD11B1 inhibits the antitumor immune response in renal cancer.
Poinot H, Dupuychaffray E, Arnoux G, Alvarez M, Tachet J, Ezzar O, Moore J, Bejuy O, Olesti E, Visconti G, González-Ruiz V, Rudaz S, Tille JC, Voegel CD, Nowak-Sliwinska P, Bourquin C, Pommier A. Poinot H, et al. Among authors: olesti e. Oncoimmunology. 2023 Nov 30;13(1):2286820. doi: 10.1080/2162402X.2023.2286820. eCollection 2024. Oncoimmunology. 2023. PMID: 38170044 Free PMC article.
The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
Martínez-Cibrián N, Ortiz-Maldonado V, Español-Rego M, Blázquez A, Cid J, Lozano M, Magnano L, Giné E, Correa JG, Mozas P, Rodríguez-Lobato LG, Rivero A, Montoro-Lorite M, Ayora P, Navarro S, Alserawan L, González-Navarro EA, Castellà M, Sánchez-Castañón M, Cabezón R, Benítez-Ribas D, Setoaín X, Rodríguez S, Brillembourg H, Varea S, Olesti E, Guillén E, Sáez-Peñataro J, de Larrea CF, López-Guillermo A, Pascal M, Urbano-Ispizua Á, Juan M, Delgado J. Martínez-Cibrián N, et al. Among authors: olesti e. Br J Haematol. 2024 Feb;204(2):525-533. doi: 10.1111/bjh.19170. Epub 2023 Oct 31. Br J Haematol. 2024. PMID: 37905734
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.
Oliver-Caldés A, González-Calle V, Cabañas V, Español-Rego M, Rodríguez-Otero P, Reguera JL, López-Corral L, Martin-Antonio B, Zabaleta A, Inogés S, Varea S, Rosiñol L, López-Díaz de Cerio A, Tovar N, Jiménez R, López-Parra M, Rodríguez-Lobato LG, Sánchez-Salinas A, Olesti E, Calvo-Orteu M, Delgado J, Pérez-Simón JA, Paiva B, Prósper F, Sáez-Peñataro J, Juan M, Moraleda JM, Mateos MV, Pascal M, Urbano-Ispizua A, Fernández de Larrea C. Oliver-Caldés A, et al. Among authors: olesti e. Lancet Oncol. 2023 Aug;24(8):913-924. doi: 10.1016/S1470-2045(23)00222-X. Epub 2023 Jul 3. Lancet Oncol. 2023. PMID: 37414060 Free article.
Determination of up to twenty carboxylic acid containing compounds in clinically relevant matrices by o-benzylhydroxylamine derivatization and liquid chromatography-tandem mass spectrometry.
Gomez-Gomez A, Olesti E, Montero-San-Martin B, Soldevila A, Deschamps T, Pizarro N, de la Torre R, Pozo OJ. Gomez-Gomez A, et al. Among authors: olesti e. J Pharm Biomed Anal. 2022 Jan 20;208:114450. doi: 10.1016/j.jpba.2021.114450. Epub 2021 Oct 29. J Pharm Biomed Anal. 2022. PMID: 34798391
27 results